Weichung Shih

4.1k total citations · 2 hit papers
31 papers, 2.8k citations indexed

About

Weichung Shih is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Weichung Shih has authored 31 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Molecular Biology, 11 papers in Endocrinology, Diabetes and Metabolism and 7 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Weichung Shih's work include Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (7 papers) and Pancreatic function and diabetes (4 papers). Weichung Shih is often cited by papers focused on Diabetes Treatment and Management (10 papers), Metabolism, Diabetes, and Cancer (7 papers) and Pancreatic function and diabetes (4 papers). Weichung Shih collaborates with scholars based in United States, Sweden and France. Weichung Shih's co-authors include Darren K. McGuire, Richard E. Pratley, Christopher P. Cannon, B Charbonnel, Francesco Cosentino, Steven G. Terra, Urszula Masiukiewicz, David Z.I. Cherney, Samuel Dagogo‐Jack and Susan Huyck and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of Clinical Oncology.

In The Last Decade

Weichung Shih

29 papers receiving 2.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes

2020 1.0k citations Christopher P. Cannon, Richard E. Pratley et al. New England Journal of Medicine profile →
Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes

2020 708 citations Darren K. McGuire, Weichung Shih et al. JAMA Cardiology profile →

Peers

Weichung Shih

EDM

SURGE

CCM

PRM

Thomas Meinicke Germany

Michel Komajda France

Itamar Raz United States

Jennifer Sugg United States

Hideaki Jinnouchi Japan

Carlos G. Santos‐Gallego United States

Ping Yan China

Egon Pfarr Germany

Leo Seman United States

Stephen D. Wiviott United States

Thomas Meinicke Germany

Weichung Shih

2.5k ×1.2

EDM

1.0k ×1.0

971 ×1.2

SURGE

405 ×0.7

CCM

138 ×0.3

PRM

Citations per year, relative to Weichung Shih Weichung Shih (= 1×) peers Thomas Meinicke

Countries citing papers authored by Weichung Shih

Since Specialization

Citations

This map shows the geographic impact of Weichung Shih's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Weichung Shih with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Weichung Shih more than expected).

Fields of papers citing papers by Weichung Shih

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Weichung Shih. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Weichung Shih. The network helps show where Weichung Shih may publish in the future.

Co-authorship network of co-authors of Weichung Shih

This figure shows the co-authorship network connecting the top 25 collaborators of Weichung Shih. A scholar is included among the top collaborators of Weichung Shih based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Weichung Shih. Weichung Shih is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Spencer, Kristen, Joseph Aisner, Mark N. Stein, et al.. (2023). A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850. Oncotarget. 14(1). 302–315. 5 indexed citations

Silk, Ann W., Biren Saraiya, Roman Groisberg, et al.. (2022). A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors. European journal of medical research. 27(1). 107–107. 13 indexed citations

Cherney, David Z.I., B Charbonnel, Francesco Cosentino, et al.. (2021). Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 64(6). 1256–1267. 109 indexed citations

Pratley, Richard E., Samuel Dagogo‐Jack, B Charbonnel, et al.. (2021). 791-P: Ertugliflozin in Older Patients with Type 2 Diabetes (T2D): An Analysis from VERTIS CV. Diabetes. 70(Supplement_1). 3 indexed citations

Dagogo‐Jack, Samuel, Richard E. Pratley, David Z.I. Cherney, et al.. (2021). Glycemic efficacy and safety of the SGLT2 inhibitor ertugliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease: an analysis from the VERTIS CV randomized trial. BMJ Open Diabetes Research & Care. 9(1). e002484–e002484. 20 indexed citations

Cosentino, Francesco, Christopher P. Cannon, David Z.I. Cherney, et al.. (2020). Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease. Circulation. 142(23). 2205–2215. 175 indexed citations

McGuire, Darren K., Weichung Shih, Francesco Cosentino, et al.. (2020). Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes. JAMA Cardiology. 6(2). 148–148. 708 indexed citations breakdown →

Cannon, Christopher P., Richard E. Pratley, Samuel Dagogo‐Jack, et al.. (2020). Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes. New England Journal of Medicine. 383(15). 1425–1435. 1011 indexed citations breakdown →

Shen, Minhong, Yi-Zhou Jiang, Yong Wei, et al.. (2019). Tinagl1 Suppresses Triple-Negative Breast Cancer Progression and Metastasis by Simultaneously Inhibiting Integrin/FAK and EGFR Signaling. Cancer Cell. 35(1). 64–80.e7. 136 indexed citations

10.

Cannon, Christopher P., Darren K. McGuire, Richard E. Pratley, et al.. (2018). DESIGN AND BASELINE CHARACTERISTICS OF THE EVALUATION OF ERTUGLIFOZIN EFFICACY AND SAFETY CARDIOVASCULAR OUTCOMES TRIAL (VERTIS-CV). Journal of the American College of Cardiology. 71(11). A1825–A1825. 55 indexed citations

11.

Cannon, Christopher P., Darren K. McGuire, Richard E. Pratley, et al.. (2018). Design and baseline characteristics of the eValuation of ERTugliflozin effIcacy and Safety CardioVascular outcomes trial (VERTIS-CV). American Heart Journal. 206. 11–23. 160 indexed citations

12.

DiPaola, Robert S., Bernadette Cracchiolo, Darlene Gibbon, et al.. (2014). Phase 2 Trial of Paclitaxel, 13-cis Retinoic Acid, and Interferon Alfa-2b in the Treatment of Advanced Stage or Recurrent Cervical Cancer. International Journal of Gynecological Cancer. 24(9). 1636–1641. 6 indexed citations

13.

Chang, Richard L., Alexander W. Wood, Min-Nung Huang, et al.. (2013). Mutagenicity and tumorigenicity of the four enantiopure bay-region 3,4-diol-1,2-epoxide isomers of dibenz[a,h]anthracene. Carcinogenesis. 34(9). 2184–2191. 11 indexed citations

14.

Mehnert, Janice M., et al.. (2010). A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in metastatic melanoma.. Journal of Clinical Oncology. 28(15_suppl). TPS309–TPS309. 7 indexed citations

15.

Saraiya, Biren, Murugesan Gounder, Jayeeta Dutta, et al.. (2008). Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anti-Cancer Drugs. 19(4). 411–420. 16 indexed citations

16.

Toppmeyer, Deborah, Murugesan Gounder, Viral Vyas, et al.. (2003). A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.. PubMed. 9(8). PI99–104. 8 indexed citations

17.

Toppmeyer, Deborah, Elizabeth Alli, Thomas Kearney, et al.. (2002). A Phase I/pilot study of sequential doxorubicin/vinorelbine: effects on p53 and microtubule-associated protein 4.. PubMed. 8(5). 1057–64. 18 indexed citations

18.

Zheng, Xi, Richard L. Chang, Katherine A. Kelly, et al.. (2001). Synergistic Effects of Clinically Achievable Concentrations of 12-O Tetradecanoylphorbol-13-acetate in Combination With all-trans Retinoic Acid, 1α,25-Dihydroxyvitamin D₃, and Sodium. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 12(9). 419–427. 18 indexed citations

19.

Gould, A. Lawrence & Weichung Shih. (1998). Modifying the design of ongoing trials without unblinding. Statistics in Medicine. 17(1). 89–100. 59 indexed citations

20.

Shih, Weichung & Sanford Weisberg. (1986). Assessing Influence in Multiple Linear Regression with Incomplete Data. Technometrics. 28(3). 231–231. 26 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact